Previous trials and clinical reports conducted in Asia have already evidenced NeuroAiD's safety and efficacy in post stroke rehabilitation, even when taken several months after the stroke's onset. This paper comes after the publication of three clinical peer reviewed papers in the first half of 2011. Firstly, the European Journal of Internal Medicine published a paper establishing a significant increase of Cerebral Blood Flow velocity after 3 months in stroke patients treated with NeuroAiD as compared to placebo. These results, in matching a better functional outcome, suggested increased angiogenesis and microcirculation activity. Secondly, Neuronal Regeneration Research published a paper suggesting that NeuroAiD may increase the recovery of vision deficits in post stroke Homonymous Hemianopsia patients. The patients in the NeuroAiD group demonstrated a 50% increase in therapeutic effects as compared to the Piracetam group. Lastly, Stroke Research and Treatment published a double-blind placebo-controlled clinical trial which was conducted on 150 patients having suffered from stroke less than 3 months ago. NeuroAiD showed a better motor recovery than placebo, and was safe as an add-on to standard ischemic stroke medications, especially in severe and moderate cases.
"This is good news for the patients", commented David Picard, CEO of Moleac. "The number of publications on NeuroAiD since the beginning of the year shows increased interest and reach for NeuroAiD. The latest papers further confirm how NeuroAiD benefits post stroke patients in cognitive and motor recovery. There is a strong urge for us to expand our clinical work to address the needs of post-cardiac ar
Copyright©2010 PR Newswire.
All rights reserved